Clearside Biomedical presented human and animal study data showing the benefits of directly injecting medication into the eye's posterior suprachoroidal space at the Association for Research in Vision and Ophthalmology 2014 annual meeting in Orlando, FL.
Researchers at Rice University in Texas have developed a new kind of drug delivery particle: a "tunable" virus that releases a treatment only in the presence of not one but two different enzymes that show elevated levels at the site of a tumor.
Braeburn Pharmaceuticals received the go-ahead from the FDA to initiate a new clinical trial of implants for the continuous subdermal delivery of buprenorphine to combat opioid dependence.
Startup Envisia Therapeutics is presenting the results of its ophthalmology research and technology allowing intracameral drug delivery at the Association for Research in Vision and Ophthalmology 2014 annual meeting in Orlando, FL.
Civitas Therapeutics announced that its inhaled formulation of levodopa for the treatment of "off episodes" associated with Parkinson's disease met its primary clinical endpoint in a Phase II trial.
Some analysts raised their eyebrows at Oramed's preliminary midstage oral insulin data in late January. Now the Jerusalem company has announced further details of the trial that bring to light a dosing issue, and shares have continued their downward spiral ever since.
Zogenix is selling its Sumavel DosePro Needle-free Delivery System for migraines to Endo International, but don't be fooled--it is maintaining ownership of the delivery technology upon which the product is based.
Johns Hopkins researchers published a study showing they can use biodegradable nanoparticles to carry DNA to brain cancer cells. The animal study suggests that these vehicles could deliver what they call "death genes" to the cells, treating the cancer while preserving healthy brain cells in the process.
Cynapsus Therapeutics' sublingually delivered reformulation of the drug used to treat advanced Parkinson's disease cleared an initial clinical hurdle, the company said April 24.
A team of chemistry professors has developed a method to monitor chemicals as they enter the skin, giving them a better idea of how fast and by which pathways the small molecules permeate the surface.
Researchers have developed a unique delivery mechanism that inhibits the respiratory syncytial virus using double-stapled peptides and nanoparticles. They believe their research has implications for the treatment of other viruses as well.
Mylan Pharmaceutical's Xulane is the first generic contraceptive transdermal patch to hit the market, marking another milestone for the delivery technology.
Researchers at the University of Texas at Arlington found that nanoparticles they were studying for radiation detection in the security arena could produce a toxic byproduct able to damage cancer cells.
One way of bypassing the immune system to deliver drugs to a tumor site is to use the immune system itself as a delivery mechanism. And now researchers have unexpectedly found that nanoparticle-encased drugs injected into mice entered immune cells called monocytes, which then carry the treatment to the correct site.
Researchers at Harvard University's Wyss Institute have developed "smart" nanoparticles out of DNA that act like a virus to bypass the immune system's defenses and deliver drugs to a tumor.
Detroit-based ProNAi picked up a $59.5 million venture capital round to support its mid-stage DNAi cancer therapy that uses liposomal delivery technology developed by Marina Biotech.
The COO of RNAi specialist Alnylam was critical of Big Pharma in the wake of Novartis' decision to slam the breaks on its RNAi research. The news made investors nervous about the future of the promising, but nascent technology and Alnylam stock price is down more than 20% in the last week.
A team of scientists from Oregon State University and Aradigm, a small pulmonary device company out of California, touted successful in vitro results for its inhaled, encapsulated ciproflaxacin treatment for infections associated with the lungs.
In an effort to localize the effects of anesthesia, researchers have turned to magnetic nanoparticles to target the delivery of ropivacaine in a proof-of-concept animal study.
At MIT, researchers have developed nanoparticles that can carry as many as three cancer drugs at a time in a precise ratio.